American | LEADERSHIP

LEADERSHIP

American Injectables is led by a team of seasoned industry professionals who are dedicated to building a robust and effective American pharmaceutical manufacturing infrastructure.

OPERATING TEAM

Adam Levitt

Chief Executive Officer

ADAM LEVITT

With over twenty-five years of experience in leading and scaling up the businesses for commercial success, Adam’s experience and expertise encompasses product launches, building sales and marketing capabilities, and extensive business development experience. Adam has forged global commercial partnerships, and is an industry leader in creating a successful business platform for CMOs and suppliers as the CEO of Strides, N.A and as Global Sr. VP Commercial Operations of Teva Pharmaceuticals. Regarded for his ability to forge strong partnerships, Adam is recognized for the strategic alliances and partnerships he has built globally. Adam brings a strategic, yet pragmatic focus as an executive, and is known as a being a “builder” and leader of profitable businesses that unlock long term value.

Ben Boling

Chief Operating Officer

BEN BOLING

Ben brings more than 30 years of operational expertise with drug manufacturing on a global level. He specializes in new plant startups, site remediations, lean transformations, technology/product transfers, integration of operations and quality units, and building effective organizational structure. Ben focuses on building, leading, and developing high-performance teams that demonstrate respect, trust, integrity, and accountability.

Gilad Shadur

Chief Financial Officer

GILAD SHADUR

Gilad Shadur joined American Injectables in April 2021 and assumes full responsibility for the financial management of the company, including IT. Prior to joining American Injectables, Gilad was CFO, R&D and Global Marketing & Portfolio at Teva Pharmaceutical. Gilad has 19 years of diverse experience as strategic finance leader and business partner across Operations, Commercial, and R&D in Generics, Branded, Biosimilars, and OTC products.

Alison Brown

Vice President Quality and Compliance

ALISON BROWN

Alison Brown is the VP Quality Assurance & Compliance at American Injectables. She joined the company in August 2021 and is responsible for the development, implementation and oversight of the Quality Management System and the Quality Assurance and Quality Control teams. In this role Alison provides leadership and guidance to ensure compliance with current Good Manufacturing Practices (cGMP) as they pertain to the local regulation and exporting countries’ regulation as applicable.

Alison has over 25 years’ experience in the pharmaceutical industry with an established career in Quality Assurance and Compliance leadership at global organizations such as Catalent, McNeil Healthcare (J&J), and TEVA Pharmaceuticals, Ltd. Alison has a proven track record in leading and responding to regulatory and customer inspections supporting domestic and global Boards of Health. She is well versed in Quality Management System development and maintenance; with an emphasis in strategic planning and execution, innovative problem solving and continuous improvement for operational excellence.

Travis Allen

Vice President Business Operations and Development

TRAVIS ALLEN

Travis is responsible for business development, corporate strategy, and companywide project management. Prior to joining American Injectables, he held roles of increasing responsibility in operations and business development at Actavent Pharmaceuticals along with experience in 503B outsourcing for hospital markets. Previously, he worked at the biotechnology firm Amgen in Scientific Affairs. Mr. Allen received his Pharm.D. from the University of Florida.

BOARD OF DIRECTORS

Subhanu Saxena

Chairman of the Board

SUBHANU SAXENA

_{As Chairman of the Board, Subhanu Saxena joins American Injectables from New Rhein Healthcare Investors. At New Rhein, he serves as a Managing Partner since 2017. Subhanu is an accomplished executive with experience in Europe, North America, Africa and Asia, and has worked in pharmaceuticals, fast moving consumer goods (FMCG), consulting, and banking.}

_{Prior to joining New Rhein, Subhanu was the Managing Director & Global Chief Executive Officer of Cipla, a global pharmaceutical manufacturing company with a presence in over 170 countries from 2013 to 2016. Prior to Cipla, from 2009 to 2012 Subhanu served as a Pharma Executive Committee Member for Novartis Pharmaceuticals responsible for Global Product Strategy and Commercialization, having previously been Country President and Pharma CEO of Novartis UK and Ireland from 2005 to 2009. In 2016, he was awarded a Finance Monthly “CEO of the Year” award for India-based CEOs.}

_{Subhanu has an MBA from INSEAD and an MA (with Honors) in Engineering Science from Oxford University. He speaks six languages, loves loud music, plays guitar, and is a lecturer and teacher of Sanskrit and Vedan.}

Greg Parekh

Board Member

GREG PAREKH

_{Greg Parekh led the investment into American Injectables and serves as a Board member. Greg founded New Rhein Healthcare Investors in 2010 and is a Managing Partner. Before launching New Rhein, Greg led the integration planning for Alcon on behalf of Novartis AG, where he previously ran the Mergers & Acquisitions group from 2004 to 2009. During his time at Novartis, Greg helped execute over 20 transactions with a total deal value of more than $70 billion. Prior to joining Novartis, Greg headed Deutsche Bank’s European Healthcare Group from 1998 to 2004. Greg joined Deutsche Bank from Bear Stearns in New York, where he started his career in 1995 as an associate in the Life Sciences group.}

_{Greg has served as a director of the companies in which New Rhein made its initial deal-by-deal investments, Novagali Pharma, SA (ophthalmology), Chase Pharmaceuticals (Alzheimer’s), and Biocartis BV (oncology diagnostics), for which Greg also served as Chief Executive Officer from 2011 to 2013. Greg presently serves on the boards of New Rhein Fund 18 portfolio companies, Softhale NV and Neuraptive Therapeutics, Inc., and is a director of Cancerlinq, a big-data digital healthcare platform and wholly owned subsidiary of the American Society of Clinical Oncology (ASCO). Greg holds a Ph.D. in Economics from Northwestern University, an executive leadership program certificate from Harvard Business School, and a dual-major B.A. from University of Rochester (magna cum laude). Greg’s hobbies include gourmet cooking, downhill skiing, and music.}

Carlo De Notaristefani

Board Member

CARLO DE NOTARISTEFANI

Carlo is an international operations senior executive with global technical, operational, and P&L experience. He has deep expertise in designing and operating global supply chains in complex regulatory environments, leading accretive M&A activity, devising and executing value creating strategies in global markets.

Since May 2020, Carlo has been the lead advisor for Manufacturing and Supply Chain to Operation Warp Speed/Federal Covid Response, the USG initiative to support acceleration of development and supply of Covid-19 vaccines and therapeutics. He has collaborated with the sponsors, suppliers and CDMOs to ensure the fast scale up of manufacturing and distribution for the US.

In Carlo’s most recent corporate position, he was Executive VP of Operations at Teva Pharmaceuticals Inc. In this role he was responsible for all Manufacturing, Technology and Capital Investments, Supply Chain, Quality and Compliance, Procurement operations, as well as the global API and CMO business. Carlo retired from this position at the end of 2019.

Before joining Teva Pharmaceuticals Inc in 2012, Carlo was the President Technical Operations and Global Support Functions for Bristol Myers Squibb between 2004 and 2011, where he significantly contributed to the transformation into a focused biopharma company.

Carlo received his Doctor’s degree in Chemical Engineering, and graduated Summa Cum Laude from University of Naples − Naples, Italy.